1Department of Surgery, Georgetown University School of Medicine, Washington, DC 20010, USA
2Center for Advanced Laparoscopic General & Bariatric Surgery, MedStar Washington Hospital Center and Georgetown University School of Medicine, Washington, DC 20010, USA
*Address for Correspondence: Timothy R Koch, MD, Professor of Medicine (Gastroenterology), Georgetown University School of Medicine, Center for Advanced Laparoscopic General & Bariatric Surgery, POB South, Suite 301, MedStar Washington Hospital Center, 110 Irving Street, NW, Washington, DC 20010, USA, Tel: +1-202 8777788; Fax: +1-877 6808198; Email: email@example.com
Dates: Submitted: 20 October 2017; Approved: 30 October 2017; Published: 31 October 2017
How to cite this article: Sharbaugh ME, Shope TR, Koch TR. Upper gut bacterial overgrowth is a potential mechanism for Glucose Malabsorption after Vertical Sleeve Gastrectomy. New Insights Obes Gene Beyond. 2017; 1: 030-035. DOI: 10.29328/journal.hodms.1001006
Copyright: © 2017 Sharbaugh ME, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: Morbid obesity; Bariatrics; Bariatric surgery; Vertical sleeve gastrectomy; Diabetes mellitus
In 1955, nutrient malabsorption following upper gut surgery was shown to be related to altered upper gut microbiome. In individuals with abdominal symptoms after Roux-en-Y gastric bypass, we have reported that small intestinal glucose malabsorption is associated with upper gut bacterial overgrowth. We hypothesize that individuals with abdominal symptoms after vertical sleeve gastrectomy have glucose malabsorption associated with upper gut bacterial overgrowth, and to test this hypothesis, bacterial overgrowth and potential glucose malabsorption are examined after sleeve gastrectomy. This is a retrospective study of individuals with medically-complicated obesity who underwent sleeve gastrectomy from 2013 to 2016 with subsequent glucose hydrogen breath testing to evaluate abdominal symptoms. A fasting breath hydrogen or methane of ≥10 PPM or rise of ≥8 PPM ≤45 minutes after oral glucose is bacterial overgrowth, while glucose malabsorption is a second rise of ≥8 PPM at >45 minutes. Seven females (mean age: 48.0 years; mean body mass index at surgery: 45.7 kg/m2) are described. Five subjects (71%) have an early rise in hydrogen or methane, while three (43%) have a second rise in hydrogen or methane >45 minutes after glucose. The mean percent excess weight loss at one year was 40% in three individuals with a second peak and 46% in four subjects without a second peak. After sleeve gastrectomy, subjects have glucose malabsorption associated with the presence of bacterial overgrowth. Completion of a larger prospective study is needed to confirm and expanding upon these findings. Further work should examine the potential effects of bacterial overgrowth on expression of intestinal glucose transporters.
In a recent international study involving 195 countries, the prevalence of obesity has reportedly doubled since 1980 in more than 70 countries with an estimated 107.7 million obese children and 603.7 million obese adults in 2015 . The rapid rise in the prevalence of obesity has created a global health crisis. Laparoscopic vertical sleeve gastrectomy (LapVSG) has been recognized as an effective surgical option for the management of medically-complicated obesity. From 2011 to 2015, LapVSG gained the forefront of bariatric surgical procedures performed in the United States, and has replaced Roux-en-Y gastric bypass (RYGB) as the most common surgical treatment of medically-complicated obesity . Indeed, LapVSG has gained international acceptance as an effective surgical option for treatment of medically-complicated obesity .
In 1955, Dr. JA Halsted described micronutrient malabsorption (e.g. vitamin B12 deficiency) following upper gut surgery associated with an altered upper gut microbiome , now termed small intestinal bacterial overgrowth or SIBO. Our previous work reported finding vitamin B1 deficiency in those individuals with SIBO after RYGB . In a follow up study of individuals with abdominal symptoms after RYGB, glucose hydrogen breath testing was used to examine the presence of SIBO and the potential malabsorption of glucose . Small intestinal glucose malabsorption was found to be associated with the presence of SIBO .
Based upon these prior studies, we hypothesize that individuals with abdominal symptoms after LapVSG also have glucose malabsorption associated with SIBO. Our aims in this present study are to determine whether there is SIBO after VSG, whether there is glucose malabsorption after VSG, whether there is an association between SIBO and glucose malabsorption, and whether glucose malabsorption may alter weight loss after LapVSG.
This human study was approved by the Human Studies Subcommittee of MedStar Research Institute (Hyattsville, MD) on December 14, 2016. Because this was determined to be a minimal risk protocol by the Human Studies Subcommittee, a waiver of informed consent was granted for this research study. This is a single institution, retrospective study completed in our large, urban community teaching hospital. This is a retrospective study of patients with medically-complicated obesity who underwent LapVSG as we have previously described  and had glucose (25 grams) hydrogen breath testing for evaluation of abdominal symptoms. LapVSG is mainly a restrictive procedure in which the gastric fundus and body are surgically excised thus resulting in a narrow, lesser-curvature based stomach (Figure 1).
Each individual’s demographic information, the preoperative presence of diabetes mellitus, the percentage of excess body weight loss (we subtracted the individual’s postoperative weight from their preoperative weight, divided that number by their preoperative excess weight, and then multiplied that result by 100) at 1 year after LapVSG, the results of glucose breath testing, and the time period between bariatric surgery and glucose hydrogen breath testing are recorded.
Glucose hydrogen breath testing
The performance of glucose- hydrogen/methane breath testing in individuals after bariatric surgery has been described . No antibiotic use was permitted for 1 month before the breath test. Individuals present for breath testing after an overnight 12 hour fast prior to the procedure. Using a breath microlyzer (Quintron Instrument Company, Milwaukee, WI), baseline end expiratory values of breath hydrogen and methane are obtained. Each subject receives a solution containing 25 grams of glucose dissolved in 240 ml of water, which is then ingested orally. The dose of glucose has been limited in our clinical laboratory to 25 grams since post-bariatric patients commonly complain of marked abdominal pain and/or diarrhea after receiving a 50 gram dose of glucose. Breath hydrogen concentrations and methane concentrations are then measured every 15 minutes for 2 hours after ingestion of glucose. Based upon a previous study  that described at least a 10 parts per million rise in breath hydrogen after 75 grams of glucose in individuals with ≥106 colony forming units/ml in jejunal aspirates, upper gut bacterial overgrowth is considered to be diagnosed by either a fasting breath hydrogen or methane of ≥10 parts per million or a rise of ≥8 parts per million ≤45 minutes after ingestion of 25 grams of glucose. An early rise in breath hydrogen or methane is accepted as reflecting glucose fermentation by bacteria in the upper gastrointestinal tract. Glucose malabsorption was defined by a second rise of ≥8 parts per million hydrogen or methane at >45 minutes after glucose. The late rise in breath hydrogen or methane is accepted to be consistent with glucose reaching the terminal ileum or entering the colon and thus being metabolized by ileocolonic flora. If there is an early rise in breath hydrogen, a later rise in breath methane is not accepted as consistent with glucose malabsorption due to the potential for production of methane from hydrogen by intraluminal bacteria. Figure 2 demonstrates the typical findings in an individual with both an early and a late rise in breath hydrogen/methane.
Statistical analysis was performed using a standardized computer program (StatView; SAS Institute Inc, Cary, NC). A p value <0.05 was considered to be significant.
Seven females are included in this study with a mean age of 48.0 years-old (range: 35 to 57 years) and a mean body mass index at the day of bariatric surgery of 45.7 kg/m2 (range: 40 to 53 kg/m2). The mean time from surgery until glucose hydrogen breath testing was 692 days (range: 307 to 1344 days).
Glucose hydrogen breath test
Figure 3 demonstrates the breath test results for these seven individuals after LapVSG. Five subjects (71%) had either an elevated fasting hydrogen/methane or an early rise in hydrogen or methane, and these findings are consistent with upper gut bacterial overgrowth. Three subjects (50%) had a rise in hydrogen or methane >45 minutes after glucose ingestion, consistent with glucose malabsorption. None of these three individuals had preoperative diabetes mellitus. However, all three of these subjects also demonstrated an early rise in breath hydrogen or methane ≤45 minutes after ingestion of 25 grams of glucose. As shown in the 2X2 table 1, these findings did not reach statistical significance.
The average percent excess weight loss at one year was 40% in three subjects with a second peak and 46% in four subjects without a second peak (p>0.05).
This feasibility study supports our hypothesis that individuals after LapVSG develop glucose malabsorption associated with the presence of upper gut bacteria. In this small study, we saw no evidence for increased percent excess weight loss in individuals who have evidence on glucose hydrogen breath testing for glucose malabsorption. There is however a dearth of information with regards to upper gut bacterial overgrowth in individuals after vertical sleeve gastrectomy, and so this study extends our prior study of the role of upper gut bacterial overgrowth after RYGB . Upper gut bacterial overgrowth could induce glucose malabsorption by altering the function of small intestinal glucose transporters. There is a sodium-dependent glucose cotransporter (SGLT1) at the apical membrane of the small bowel enterocyte [9,10]. At the basolateral side of the enterocyte membrane, a second glucose transporter termed GLUT2 has been identified and GLUT2 has been thought to be important for the process of simple glucose diffusion [10,11]. There is presently minimal information about the potential role of upper gut bacteria in altering the expression or function of enterocyte proteins.
Glucose malabsorption after bariatric surgery is an interesting potential origin for postoperative weight loss. Presently proposed mechanisms of weight loss after LapVSG include restriction of dietary intake of calories and a reduction in the release of the orexigenic hormone, ghrelin . As a potential secondary role of glucose malabsorption, a number of potential mechanisms have been proposed to be involved in the improvement of glycemic control after bariatric surgery including changes in secretion of gastrointestinal hormones, bacterial flora, bile acids, intestinal gluconeogenesis, gastrointestinal motility, and a potential role for adipose tissue in the production of inflammatory mediators .
The major weakness of this present study is the concern about the potential for rapid transit of glucose to the terminal ileum or cecum. It has been reported from the Medical College of Wisconsin in Milwaukee, WI that glucose commonly reaches the cecum during a breath test . In their study, upper GI surgery was defined as surgery involving the esophagus, stomach, or small bowel. Among 54 patients with upper GI surgery, 30% of these patients had evidence for passage of glucose to the cecum. Their result appears similar to the 43% of individuals that our present study has identified as having evidence for glucose malabsorption after LapVSG. In the Milwaukee study, however, the authors used 80 grams of glucose compared to the smaller dose of 25 grams of glucose that we use. It was also not clear whether the tracer that was used for scintigraphy (Tc-99m diethylenetriaminepentaacetic acid) altered small bowel motility. Small bowel transit could be validated using other methods including small intestinal follow through x-rays with barium or studies of small intestinal capsule endoscopy.
Studies of small bowel motility after LapVSG have utilized liquid ingestion, semi-solid meals, and solid meals. In a study of liquid ingestion of 75 grams of glucose after LapVSG, small bowel transit was estimated by cine MRI scans and it appeared that transit to the terminal ileum was accelerated postoperatively . An important result of this study was that the authors appeared to demonstrate that glucose was reaching the terminal ileum after LapVSG and thus glucose was not being absorbed. Using scintigraphy with a radiolabeled semisolid meal, it has been reported that LapVSG results in both a more rapid duodenum to terminal ileum transit time as well as delayed cecal filling . It is difficult to know how these two opposite processes might alter small intestinal glucose absorption. In a third study, small bowel transit time after LapVSG as estimated by scintigraphy following ingestion of a radiolabeled solid meal was reported to be 199.6+/-65.7 minutes . This third study does not support rapid oral-cecal transit after LapVSG.
In summary, this study provides evidence that individuals after LapVSG have glucose malabsorption associated with the presence of upper gut bacterial overgrowth. Completion of a larger prospective study will be important for confirming and expanding upon these present findings and hypothesis. Further work is needed to examine the potential effects of upper gut bacterial overgrowth on expression of small intestinal glucose transporters.